Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology
- PMID: 38455708
- PMCID: PMC10919138
- DOI: 10.1177/17588359241231260
Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology
Abstract
Lung cancer poses a global health challenge and stands as the leading cause of cancer-related deaths worldwide. However, its incidence, mortality, and characteristics are not uniform across all regions worldwide. Understanding the factors contributing to this diversity is crucial in a prevalent disease where most cases are diagnosed in advanced stages. Hence, prevention and early diagnosis emerge as the most efficient strategies to enhance outcomes. In Western societies, tobacco consumption constitutes the primary risk factor for lung cancer, accounting for up to 90% of cases. In other geographic locations, different significant factors play a fundamental role in disease development, such as individual genetic predisposition, or exposure to other carcinogens such as radon gas, environmental pollution, occupational exposures, or specific infectious diseases. Comprehensive clinical and molecular characterization of lung cancer in recent decades has enabled us to distinguish different subtypes of lung cancer with distinct phenotypes, genotypes, immunogenicity, treatment responses, and survival rates. The ultimate goal is to prevent and individualize lung cancer management in each community and improve patient outcomes.
Keywords: NSCLC; geographic differences; molecular diagnosis; molecular epidemiology.
© The Author(s), 2024.
Conflict of interest statement
JCL: Lectures and educational activities: Kyowa Kirin; Travel, Accommodations, Expenses: Rovi, Pierre-Fabre. MGP: The author declares no conflict of interest. JA: advisory board: BMS and AstraZeneca; consultant: MSD and Janssen. CB: The author declares no conflict of interest. NS: The author declares no conflict of interest. HOAS: Research support: AstraZeneca, Merck. HL: Advisory: Boehringer-Ingelheim, Celgene, Eli-Lilly, Illumina, Janssen, Novartis, Merck Sereno, Pfizer, Takeda, George Clinical; Speakers’ Bureau: AbbVie, Amgen, Bayer, Eisai, Eli-Lilly, Guardant Health, Novartis; Travel Support: Bayer, Boehringer-Ingelheim, MSD, Novartis, Pfizer; Research Funding: MSD, Mundipharma, Novartis; Others: Member, Pharmacy and Poisons (Registration of Pharmaceutical Products and Substances: Certification of Clinical Trial/Medicinal Test) Committee, Pharmacy & Poisons Board of Hong Kong. MF: The author declares no conflict of interest. GR: The author declares no conflict of interest. LM: Lectures and educational activities: Bristol-Myers Squibb, AstraZeneca, Roche, Takeda, Janssen, Pfizer, MSD; Consulting, advisory role: Roche, Takeda, Janssen, MSD; Research Grants: Bristol-Myers Squibb, Amgen, Stilla, Inivata, AstraZeneca, Gilead; Travel, Accommodations, Expenses: Bristol-Myers Squibb, Roche, Takeda, AstraZeneca, Janssen.
Figures

Similar articles
-
The Minderoo-Monaco Commission on Plastics and Human Health.Ann Glob Health. 2023 Mar 21;89(1):23. doi: 10.5334/aogh.4056. eCollection 2023. Ann Glob Health. 2023. PMID: 36969097 Free PMC article. Review.
-
Epidemiology of lung cancer.Contemp Oncol (Pozn). 2021;25(1):45-52. doi: 10.5114/wo.2021.103829. Epub 2021 Feb 23. Contemp Oncol (Pozn). 2021. PMID: 33911981 Free PMC article. Review.
-
An overview of the North American residential radon and lung cancer case-control studies.J Toxicol Environ Health A. 2006 Apr;69(7):599-631. doi: 10.1080/15287390500260960. J Toxicol Environ Health A. 2006. PMID: 16608829 Review.
-
Occupation and cancer - follow-up of 15 million people in five Nordic countries.Acta Oncol. 2009;48(5):646-790. doi: 10.1080/02841860902913546. Acta Oncol. 2009. PMID: 19925375
-
Longitudinal relationships between lung cancer mortality rates, smoking, and ambient air quality: a comprehensive review and analysis.Crit Rev Toxicol. 2019 Oct;49(9):790-818. doi: 10.1080/10408444.2019.1700210. Epub 2020 Jan 27. Crit Rev Toxicol. 2019. PMID: 31985340 Review.
Cited by
-
Aptamers: Design, Theory, and Applications to Diagnosis and Therapy for Diseases.MedComm (2020). 2025 May 19;6(5):e70180. doi: 10.1002/mco2.70180. eCollection 2025 May. MedComm (2020). 2025. PMID: 40391083 Free PMC article. Review.
-
Dissecting the intratumoral microbiome landscape in lung cancer.Front Immunol. 2025 Jul 24;16:1614731. doi: 10.3389/fimmu.2025.1614731. eCollection 2025. Front Immunol. 2025. PMID: 40777004 Free PMC article. Review.
-
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study).Ther Adv Med Oncol. 2025 Jun 26;17:17588359251351449. doi: 10.1177/17588359251351449. eCollection 2025. Ther Adv Med Oncol. 2025. PMID: 40585875 Free PMC article.
-
KLF13 promotes ferroptosis and chemosensitivity in lung adenocarcinoma.BMC Biol. 2025 Jul 1;23(1):178. doi: 10.1186/s12915-025-02303-x. BMC Biol. 2025. PMID: 40597044 Free PMC article.
-
Repression of ZNFX1 by LncRNA ZFAS1 mediates tobacco-induced pulmonary carcinogenesis.Cell Mol Biol Lett. 2025 Apr 10;30(1):44. doi: 10.1186/s11658-025-00705-x. Cell Mol Biol Lett. 2025. PMID: 40211119 Free PMC article.
References
-
- Sung H, Ferlay J, Siegel RL, et al.. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249. - PubMed
-
- American Cancer Society. Lung cancer risk factors. Smoking & Lung Cancer, https://www.cancer.org/cancer/types/lung-cancer/causes-risks-prevention/... (accessed 20 September 2023).
Publication types
LinkOut - more resources
Full Text Sources
Medical